307 related articles for article (PubMed ID: 27030595)
21. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
[TBL] [Abstract][Full Text] [Related]
22. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
Hare LM; Schwarz Q; Wiszniak S; Gurung R; Montgomery KG; Mitchell CA; Phillips WA
Dev Biol; 2015 Aug; 404(1):14-26. PubMed ID: 25958091
[TBL] [Abstract][Full Text] [Related]
23. Shear stress and pathophysiological PI3K involvement in vascular malformations.
Abdelilah-Seyfried S; Ola R
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747293
[TBL] [Abstract][Full Text] [Related]
24. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
25. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
[TBL] [Abstract][Full Text] [Related]
26. Venous malformations: PIK3CA mutations guide new treatments.
Dbouk HA
Oncotarget; 2016 Aug; 7(31):48852-48853. PubMed ID: 27447853
[No Abstract] [Full Text] [Related]
27. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
28. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
[TBL] [Abstract][Full Text] [Related]
29. Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations.
Ye C; Pan L; Huang Y; Ye R; Han A; Li S; Li X; Wang S
J Vasc Surg; 2011 Dec; 54(6):1760-8. PubMed ID: 21962923
[TBL] [Abstract][Full Text] [Related]
30. [Somatic activating PIK3CA mutation and unifocal venous malformation].
Dereure O
Ann Dermatol Venereol; 2016 Apr; 143(4):328-9. PubMed ID: 27016201
[No Abstract] [Full Text] [Related]
31. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations in vascular malformations.
Castillo SD; Baselga E; Graupera M
Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
[TBL] [Abstract][Full Text] [Related]
33. Review of the endothelial pathogenic mechanism of TIE2-related venous malformation.
Du Z; Zheng J; Zhang Z; Wang Y
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):740-748. PubMed ID: 28818232
[TBL] [Abstract][Full Text] [Related]
34. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component.
Jauhiainen S; Ilmonen H; Vuola P; Rasinkangas H; Pulkkinen HH; Keränen S; Kiema M; Liikkanen JJ; Laham-Karam N; Laidinen S; Beter M; Aavik E; Lappalainen K; Lohi J; Aronniemi J; Örd T; Kaikkonen MU; Salminen P; Tukiainen E; Ylä-Herttuala S; Laakkonen JP
Elife; 2023 May; 12():. PubMed ID: 37199488
[TBL] [Abstract][Full Text] [Related]
35. Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation.
Huo R; Yang Y; Sun Y; Zhou Q; Zhao S; Mo Z; Xu H; Wang J; Weng J; Jiao Y; Zhang J; He Q; Wang S; Zhao J; Wang J; Cao Y
Angiogenesis; 2023 May; 26(2):295-312. PubMed ID: 36719480
[TBL] [Abstract][Full Text] [Related]
36. Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation.
Aw WY; Cho C; Wang H; Cooper AH; Doherty EL; Rocco D; Huang SA; Kubik S; Whitworth CP; Armstrong R; Hickey AJ; Griffith B; Kutys ML; Blatt J; Polacheck WJ
Sci Adv; 2023 Feb; 9(7):eade8939. PubMed ID: 36791204
[TBL] [Abstract][Full Text] [Related]
37. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
Martinez-Corral I; Zhang Y; Petkova M; Ortsäter H; Sjöberg S; Castillo SD; Brouillard P; Libbrecht L; Saur D; Graupera M; Alitalo K; Boon L; Vikkula M; Mäkinen T
Nat Commun; 2020 Jun; 11(1):2869. PubMed ID: 32513927
[TBL] [Abstract][Full Text] [Related]
38. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
[TBL] [Abstract][Full Text] [Related]
39. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
40. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]